BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11136572)

  • 1. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma.
    Costa S; Terzano P; Bovicelli A; Martoni A; Angelelli B; Santini D; Ceccarelli C; Lipponen P; Erzén M; Syrjänen S; Syrjänen K
    Gynecol Oncol; 2001 Jan; 80(1):67-73. PubMed ID: 11136572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome.
    Costa S; Terzano P; Santini D; Ceccarelli C; Martoni A; Angelelli B; Panetta A; Bovicelli A; Cristiani P; Lipponen P; Erzén M; Syrjänen S; Syrjänen K
    Am J Clin Pathol; 2001 Nov; 116(5):729-37. PubMed ID: 11710691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
    Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
    Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma.
    Ramasami S; Kerr KM; Chapman AD; King G; Cockburn JS; Jeffrey RR
    J Pathol; 2000 Dec; 192(4):427-32. PubMed ID: 11113858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study on induction chemotherapy with cisplatin, epirubicin, etoposide and bleomycin in cervical cancer stage Ib, IIa and IIb.
    Panetta A; Angelelli B; Martoni A
    Anticancer Res; 1999; 19(1B):765-8. PubMed ID: 10216490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
    Joo M; Lee HK; Kang YK
    Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44v6 as a prognostic factor in cervical carcinoma FIGO stage IB.
    Bouda J; Boudova L; Hes O; Havir M; Tempfer C; Kohlberger P; Svoboda T; Rokyta Z; Speiser P
    Anticancer Res; 2005; 25(1B):617-22. PubMed ID: 15816636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.
    Chen H; Liang C; Zhang L; Huang S; Wu X
    Gynecol Oncol; 2008 Sep; 110(3):308-15. PubMed ID: 18606439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
    Sugiyama T; Nishida T; Hasuo Y; Fujiyoshi K; Yakushiji M
    Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.
    Takeshima N; Umayahara K; Fujiwara K; Hirai Y; Takizawa K; Hasumi K
    Gynecol Oncol; 2006 Nov; 103(2):618-22. PubMed ID: 16777200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy.
    Lai CH; Hsueh S; Chang TC; Tseng CJ; Huang KG; Chou HH; Chen SM; Chang MF; Shum HC
    Gynecol Oncol; 1997 Mar; 64(3):456-62. PubMed ID: 9062150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix.
    Serur E; Mathews RP; Gates J; Levine P; Maiman M; Remy JC
    Gynecol Oncol; 1997 May; 65(2):348-56. PubMed ID: 9159350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of bulky stage IB and IA cervical cancer patients treated by radical hysterectomy with and without neoadjuvant chemotherapy: long-term follow-up.
    Manusirivithaya S; Chareoniam V; Pantusart A; Isariyodom P; Srisomboon J
    J Med Assoc Thai; 2001 Nov; 84(11):1550-7. PubMed ID: 11853297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma.
    Ayhan A; Baykal C; Al A; Ayhan A
    Gynecol Oncol; 2001 Dec; 83(3):569-74. PubMed ID: 11733974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
    Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis.
    dos Reis R; Frumovitz M; Milam MR; Capp E; Sun CC; Coleman RL; Ramirez PT
    Gynecol Oncol; 2007 Dec; 107(3):458-63. PubMed ID: 17854872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of neoadjuvant chemotherapy for locally advanced cervical cancinoma].
    Cheng XD; Lü WG; Ye F; Chen HZ; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):95-8. PubMed ID: 16640856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neoadjuvant chemotherapy for advanced cervical cancer].
    Kodama J; Ikuhashi H; Hongo A; Mizutani Y; Miyagi Y; Yoshinouchi M; Kobashi Y; Okuda H; Kudo T
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):89-92. PubMed ID: 9987503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
    Peng J; Lu JJ; Zhu J; Xu Y; Lu H; Lian P; Cai G; Cai S
    Cancer J; 2008; 14(1):54-61. PubMed ID: 18303484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.